Shreya launches oral insulin spray in India
This article was originally published in Scrip
Shreya Life Sciences has launched the world's first recombinant DNA human insulin buccal spray (marketed as Oral-Recosulin) in India, under an alliance with Generex Biotechnologyof the US. The product is based on Generex's proprietary platform technology for the delivery of drugs into the body through the oral cavity (with no deposit in the lungs).
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.